Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 12/20 | 0.73 |
| ▸ | PRKCI | P41743 | 1/20 | 0.61 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 13/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521029 | 0.85 | AGXT (1.00) | AGXTIDO1CYP3A4 | |
| SCHEMBL18885245 | 0.82 | PRKCI (0.61) | AGXTPRKCIPRMT6HRH3CYP3A4 | |
| SCHEMBL301749 | 0.79 | PRKCI (0.67) | PRKCIPRMT6HRH3CYP3A4CYP17A1 | |
| SCHEMBL29059534 | 0.79 | PRKCI (0.57) | AGXTPRKCIPRMT6HRH3CYP3A4 | |
| SCHEMBL1521252 | 0.79 | AGXT (0.73) | AGXTIDO1CYP3A4 | |
| SCHEMBL1521149 | 0.79 | AGXT (0.73) | AGXTIDO1CYP3A4 | |
| SCHEMBL15677919 | 0.78 | PRKCI (0.56) | AGXTPRKCIPRMT6HRH3CYP3A4 | |
| Hydrochloric Acid SCHEMBL972408 | 0.78 | PRKCI (0.65) | PRKCIPRMT6HRH3CYP3A4CYP17A1 | |
| Hydrochloric Acid SCHEMBL970902 | 0.78 | PRKCI (0.65) | PRKCIPRMT6HRH3CYP3A4CYP17A1 | |
| Hydrochloric Acid SCHEMBL14686234 | 0.77 | AGXT (0.71) | AGXTIDO1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227233-B1 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2013-02-13 | — | — | EP | claimed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | claimed |
| EP-2227233-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2010-09-15 | — | — | EP | claimed |
| WO-2009073620-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-06-11 | — | — | WO | claimed |
| WO-2019051198-A1 | PRODRUG INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2019-03-14 | — | — | WO | disclosed |
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| EP-2227233-B1 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | AGXT 365/4885PRKCI 3815/4885PRMT6 393/4885 |
| US-20130289083-A1 | IDO Inhibitors | IDO1, IDO2, INMT | AGXT 285/4885PRKCI 4344/4885PRMT6 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.